A phase I double-blind, randomised study of Motrem (LR-12) in healthy volunteers

Trial Profile

A phase I double-blind, randomised study of Motrem (LR-12) in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs LR 12 (Primary)
  • Indications Myocardial infarction; Septic shock
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Most Recent Events

    • 15 Nov 2017 According to an Inotrem media release, based on the data of this trial, European Medicines Agency (EMA) has granted access to its PRIority MEdicines (PRIME) scheme for MOTREMTM in the field of septic shock.
    • 26 Sep 2016 New trial record
    • 13 Sep 2016 Results published in the Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top